DMRA
Damora Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$30.06
+7.36%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.52
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.39
- EPS estimate
- -$0.41
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 1
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +5.8%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $45
- PT range
- $40 – $50
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026